Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma

Eur J Haematol. 2019 Jul;103(1):35-42. doi: 10.1111/ejh.13239. Epub 2019 May 30.

Abstract

Objective: Angioimmunoblastic T-cell lymphoma (AITL) is frequently associated with autoimmune cytopenia (AIC). Whether such patients have a particular phenotype and require particular management is unclear.

Method: Angioimmunoblastic T-cell lymphoma patients from the multicentric database of the Lymphoma Study Association presenting with AIC during disease course were included and matched to AITL patients without AIC (1/5 ratio).

Results: At diagnosis, AIC patients (n = 28) had more spleen and bone marrow involvement (54% vs 19% and 71% vs 34%, P < 0.001), Epstein-Barr virus replication (89% vs 39%, P < 0.001), gamma globulin titers (median 23 vs 15 g/L, P = 0.002), and proliferating B cells and plasmablasts in biopsies, as compared to control patients (n = 136). The 28 AIC patients had 41 episodes of AIC, diagnosed concomitantly with AITL in 23 (82%) cases. After a median follow-up of 24 months (range 3-155), 10 patients relapsed, all associated with AITL relapse.

Conclusion: Our results provide new insight into AIC associated with AITL by highlighting the significant interplay between AITL and B-cell activation leading to subsequent autoimmunity.

Keywords: angioimmunoblastic T-cell lymphoma; autoimmune hemolytic anemia; immune thrombocytopenia; plasmablast; pure red cell aplasia.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autoimmune Diseases / complications*
  • Autoimmune Diseases / diagnosis
  • Biopsy
  • Disease Management
  • Disease Susceptibility
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / diagnosis*
  • Immunoblastic Lymphadenopathy / etiology
  • Immunoblastic Lymphadenopathy / mortality
  • Immunoblastic Lymphadenopathy / therapy*
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphoma, T-Cell / diagnosis*
  • Lymphoma, T-Cell / etiology
  • Lymphoma, T-Cell / mortality
  • Lymphoma, T-Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pancytopenia / complications*
  • Pancytopenia / diagnosis
  • Phenotype
  • Retrospective Studies
  • Symptom Assessment
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous